Clinical Trials

Clinical Trial Detail

Return to search results.

Abatacept as GVHD Prophylaxis Phase 2

Complete title: Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial

Research Study Number       2692.00
    
Principal Investigator       Leslie Kean
    
Phase       Pilot

Look up trial at NIH

Research Study Description

This is a phase II multi-center, randomized, double blind, placebo-controlled trial.

The investigators are doing this study to see if a new drug, abatacept, can be used together with a calcineurin inhibitor (cyclosporine or tacrolimus) and methotrexate to provide better protection against Acute Graft versus Host Disease (aGvHD) without causing more infections.

Funding Source - FDA OOPD

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.



Research Study Number       2692.00
    
Contact       Shauna Sinclair
    
Telephone       206/987-2553
    
   

Keywords
Acute Lymphoid Leukemia (ALL); Acute Myeloid Leukemia (AML); Autoimmune Diseases; Hematologic Malignancies; Myelodysplastic and Myeloproliferative Syndromes (MDS and MPD); Chronic Graft Versus Host Disease (cGVHD)

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.